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SHP2: when cardiology
meets hematology
Cécile Oury and Patrizio Lancellotti | University of Liège
In this issue of Blood, Bellio et al identified a causal link between a platelet
signaling defect and bleeding in patients with Noonan syndrome (NS)
who have activating mutations of Src homology 2 (SH2) domain-containing
phosphatase 2 (SHP2).1
NS is a developmental disorder affecting
1 in every 1000 to 2500 people.2 This
clinically and genetically heterogeneous
syndrome is commonly characterized by
defects in the RAS/MAPK cell signaling
pathway. Although multiple gene muta-
tions can cause NS, about half the cases
are caused by mutations in the PTPN11
gene. Affected individuals most often
present with distinctive facial features,
short stature, chest deformity, and a wide
spectrum of congenital heart diseases.
Disordered bleeding has been reported
for 30% to 65% of individuals with NS and
has consistently been associated with
mutations in the PTPN11 gene. Bleeding
is often mild with symptoms such as ex-
cessive bruising, epistaxis, or menorrhagia,
but it can become severe after surgical
procedures. Defects of 1 or several coag-
ulation factors or thrombocytopenia have
been described but without any consistent
association with bleeding episodes.
It is noteworthy that the study by Bellio
et al is the first to describe a genetic
cause of thrombopathy resulting from a
platelet signaling defect linked to dis-
ordered bleeding. So far, only a few
inherited platelet disorders have been
related to a platelet signaling defect such
as autosomal recessive gene mutations
in PLA2G4A (Ghosal syndrome), TBXSA1,
and GNAS.3 However, whether these
specific platelet defects are responsible
for bleeding remains unknown.
The study by Bellio et al provides the
first mechanistic explanation for bleeding
in patients with PTPN11 mutations. The
authors used genetically engineered
mouse models and blood samples from
NS patients to demonstrate that muta-
tions of this gene can cause a platelet
signaling defect. The protein encoded by
PTPN11 is the ubiquitously expressed
classical nonreceptor protein tyrosine
phosphatase (PTP) SHP2.4 This protein
has 2 tandem N-terminal SH2 domains, a
catalytic PTP domain, a C-terminal tail with
2 tyrosine phosphorylation sites (Y542
and Y580), and a proline-rich region. At
resting state, SH2 domain blocks access to
SHP2 substrates by binding to its active site
pocket. Upon ligand-receptor interaction,
the N-SH2 domain preferentially binds to
tyrosine-phosphorylated proteins such as
receptor tyrosine kinase or scaffold pro-
teins to open up the phosphatase active
site, resulting in catalytic activation of
SHP2. Mutations causing NS result in
SHP2 gain-of-function by destabilizing
the catalytically inactive conformation of
the protein, which prolongs ligand-
dependent signal transduction. In addi-
tion to NS, loss-of-function mutations of
SHP2 can cause a rare NS-related syn-
drome, NS with multiple lentigines (NSML).
Intriguingly, patients with NSML can also
present with disordered bleeding.
Previous studies in mice with megakar-
yocyte- and platelet-specific deficiencies
indicate that SHP2 contributes to throm-
bus stabilization under high shear stress
without dramatically interfering with he-
mostasis.5 Indeed, platelet aggregation
induced by collagen, adenosine diphos-
phate, or thrombin occurred normally in
the absence of SHP2. In sharp contrast
to these findings, Bellio et al showed a
proximal collagen receptor signaling de-
fect in mice heterozygous for the gain-
of-function D61G mutation in SHP2.
Ex vivo and in vivo thrombus formation
were also impaired, and tail bleeding
time was prolonged in most animals,
proving the defective primary hemostasis.
Hence, these data nicely recapitulated the
bleeding diathesis of NS patients with
gain-of-functionmutations of SHP2. These
results were validated with blood samples
from NS patients who bear different gain-
of-function mutations of SHP2. Despite
variable Tosetto bleeding scores ranging
from normal to high, platelets from all
patients displayed defective aggregation
in response to low concentrations of col-
lagen as well as impaired thrombus for-
mation on a collagen-coated surface
under flow.Conversely, platelets frommice
expressing a loss-of-function SHP2 mutant
showed enhanced response to low con-
centrations of collagen, which further con-
firmed the role of SHP2 in regulating
collagen receptor signaling. Thrombus
formation was also increased under high
shear stress. Ferric chloride–induced oc-
clusive thrombosis and bleeding time were
normal, in agreement with the existence
of a mild shear-dependent prothrombotic
tendency associated with loss-of-function
mutations of SHP2. Accordingly, blood
samples from 3 NSML patients depicted
enhanced thrombus growth on a collagen
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surface under high shear stress. Platelet
aggregation induced by collagen occurred
normally, which further excluded major
platelet hyperreactivity under low non-
pathological shear stress.
Another prominent feature of NS caused
by mutations in PTPN11 is pulmonary
valve stenosis (PVS).2,6 In NS, because of
tissue overgrowth, pulmonary valve leaf-
lets are thickened and often dysplastic,
leading to impaired valve mobility and
opening, which hinders blood flow from
the right ventricle to the lungs. This con-
dition can result in obstruction of the right
ventricular outflow tract, which necessi-
tates surgical or transcatheter pulmonary
valve replacement (PVR).7 In PVS, valve
stenosis increases the systolic pressure
gradient, which can reach peak values
.64 mmHg. In severe aortic stenosis (AS),
it has been reported that a high pressure
gradient and the resulting high shear
stress induce cleavage of von Willebrand
factor (VWF) by the metalloproteinase
ADAMTS-13, leading to secondary loss of
high-molecular-weight multimer (HMWM)
VWF.8 Nevertheless, the association be-
tween the loss of HMWMs andASbleeding
remains uncertain. But because cleaved
VWF interacts less efficiently with plate-
lets and collagen, this phenomenon could
at least partially explain the occurrence
of acquired von Willebrand disease and
Heyde’s syndrome in AS. Interestingly,
even though the pressure gradients are
lower in PVS than in AS, a small study
conducted with 15 NS patients suggested
a relationship between PVS severity, loss
of HMWMs, and bleeding diathesis in
some of the patients.9 Thus, on the basis
of that study and the work of Bellio et al,
we can assume that multiple factors are
likely to contribute to bleeding in NS
patients, including platelet signaling de-
fects, coagulation impairments, severity of
PVS, and subsequent loss of HMWMs (see
figure). Hence, thorough characterizationof
platelet function (eg, platelet aggregometry
and shear-dependent PFA-200 analysis),
coagulation, and heart valve defects should
be part of NS clinical management to
anticipate any procedural risk of major
bleeding, particularly in patients under-
going PVR. Finally, further studies should
investigate the association between PVS
severity, platelet dysfunction, and bleed-
ing not only in NS but also in PVS from
other etiologies.6
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Loss of HMWM VWF
? 
Coagulation defect ? Thrombocytopenia ?
Noonan syndrome
Bleeding diathesis
Multiple mechanisms likely contribute to disordered bleeding in patients with NS caused by gain-of-function
mutations of SHP2.
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